Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milvexian. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 known ✓ | P03951 | 20/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 8/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 1/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 1/20 | 1.00 |
| ▸ | F7 | P08709 | 1/20 | 1.00 |
| ▸ | CTRB1 | P17538 | 1/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 1/20 | 1.00 |
| ▸ | CTRL | P40313 | 1/20 | 1.00 |
| ▸ | CTRB2 | Q6GPI1 | 1/20 | 1.00 |
| ▸ | CTRC | Q99895 | 1/20 | 1.00 |
| ▸ | KLK1 | P06870 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milvexian SCHEMBL29372568 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982996 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982794 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29491830 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982989 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982998 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| SCHEMBL17661921 | 0.96 | F11 (0.92) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16972161 | 0.95 | F11 (0.91) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29491750 | 0.95 | F11 (0.91) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29491953 | 0.95 | F11 (0.91) | F11KLKB1F2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260063650-A1 | METHOD FOR EXCLUDING FACTOR XIA INHIBITORS IN PATIENT SAMPLES | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2026-03-05 | — | — | US | claimed |
| EP-4703478-A1 | METHOD FOR THE EXCLUSION OF FACTOR XIA INHIBITORS IN PATIENT SAMPLES | Siemens Healthcare Diagnostics Products GmbH (DE) | 2026-03-04 | — | — | EP | claimed |
| EP-4698163-A1 | USE OF MILVEXIAN IN THE TREATMENT AND PREVENTION OF THROMBOTIC CONDITIONS IN PATIENTS WITH ATRIAL FIBRILATION | Bristol-Myers Squibb Company (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260034130-A1 | USE OF MILVEXIAN FOR TREATING OR PREVENTING ISCHEMIC STROKE | BRISTOL MYERS SQUIBB CO (US) | 2026-02-05 | — | — | US | claimed |
| US-12527766-B2 | Methods of treating acute coronary syndrome using 3,3′-diindolylmethane | BOULDER BIOSCIENCE LLC (US) | 2026-01-20 | — | — | US | claimed |
| EP-4661846-A1 | MILVEXIAN PHARMACEUTICAL COMPOSITIONS | Bristol-Myers Squibb Company (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2025224678-A1 | SOLID STATE FORMS OF MILVEXIAN AND PROCESS FOR PREPARATION THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-10-30 | — | — | WO | claimed |
| EP-4565231-A1 | USE OF MILVEXIAN FOR TREATING OR PREVENTING ISCHEMIC STROKE | Bristol-Myers Squibb Company (US) | 2025-06-11 | — | — | EP | claimed |
| CN-120118085-A | Preparation method of Milvexian | 中国药科大学 | 2025-06-10 | — | — | CN | claimed |
| WO-2025099743-A1 | PROCESS FOR PREPARATION OF MILVEXIAN AND SOLID-STATE FORMS THEREOF | DR. REDDY’S LABORATORIES LIMITED (IN) | 2025-05-15 | — | — | WO | claimed |
| WO-2024220803-A1 | USE OF MILVEXIAN IN THE TREATMENT AND PREVENTION OF THROMBOTIC CONDITIONS IN PATIENTS WITH ATRIAL FIBRILATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-24 | — | — | WO | claimed |
| WO-2024220799-A1 | USE OF MILVEXIAN FOR TREATING OR PREVENTING ADVERSE CEREBROVASCULAR EVENTS OR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS HAVING ACUTE CORONARY SYNDROME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-24 | — | — | WO | claimed |
| WO-2024220809-A1 | USE OF MILVEXIAN IN THE TREATMENT AND PREVENTION OF THROMBOTIC CONDITIONS IN PATIENTS WITH CARDIOVASCULAR OR CEREBROVASCULAR DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-24 | — | — | WO | claimed |
| CN-118688326-A | High-precision determination K2Method for preparing XIa inhibitor concentration in EDTA human blood plasma | 华润生物医药有限公司 | 2024-09-24 | — | — | CN | claimed |
| US-20240285581-A1 | METHODS OF TREATING ACUTE CORONARY SYNDROME USING 3,3'-DIINDOLYLMETHANE | BOULDER BIOSCIENCE LLC | 2024-08-29 | — | — | US | claimed |
| WO-2024167899-A1 | MILVEXIAN PHARMACEUTICAL COMPOSITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-15 | — | — | WO | claimed |
| CN-118302166-A | Mi Erwei A for preventing and treating vascular embolism | 百时美施贵宝公司 | 2024-07-05 | — | — | CN | claimed |
| WO-2024030409-A1 | USE OF MILVEXIAN FOR TREATING OR PREVENTING ISCHEMIC STROKE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-08 | — | — | WO | claimed |
| WO-2023096800-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-01 | — | — | WO | claimed |
| WO-2023043999-A1 | MILVEXIAN FOR PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527766-B2 | Methods of treating acute coronary syndrome using 3,3′-diindolylmethane | CDIPT, DAGLA, PTDSS2 | F11 394/4885KLKB1 2322/4885F2 147/4885 |
| US-20260034130-A1 | USE OF MILVEXIAN FOR TREATING OR PREVENTING ISCHEMIC STROKE | TIMP3, PLAT, MMP13 | F11 8/4885KLKB1 1028/4885F2 65/4885 |
| US-20260063650-A1 | METHOD FOR EXCLUDING FACTOR XIA INHIBITORS IN PATIENT SAMPLES | TFPI, F11, F13B | F11 2/4885KLKB1 156/4885F2 4/4885 |
| US-20240285581-A1 | METHODS OF TREATING ACUTE CORONARY SYNDROME USING 3,3'-DIINDOLYLMETHANE | TNNI3, PLAT, ADAMTS13 | F11 490/4885KLKB1 241/4885F2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.